Orlistat mouth rinse: Using the tongue to deliver antiobesity medication in a double‐blind randomized crossover pilot trial
Authors' conclusion
Orlistat decreases long-chain fatty acid (LCFA) absorption by inhibiting lipases that breakdown triglycerides. Orlistat mouth rinse decreased fat intake in high-fat consumers, suggesting that orlistat inhibited the detection of LCFAs from the high-fat test meal. Lingual delivery of orlistat is predicted to eliminate the risk of oil incontinence and promote weight loss in individuals who prefer fat.
Study context
- Population
- Participants with BMI 25–30 kg/m²; divided into low- or high-fat consumers by fat calories after placebocrossover
- Participants
- 10 participants
- Comparison
- Orlistat mouth rinse vs placebo before a high-fat meal
- Primary endpoint
- Intake of a high-fat meal (total and fat calories consumed)
Methodological detailsdouble-blind, balanced order
- Double-blind
- Balanced order
Primary result
As reported in the abstract
Total and fat calories consumed during high-fat meal
- Orlistat mouth rinse decreased total and fat calories consumed in high-fat consumers (P < 0.05)
- Orlistat mouth rinse did not alter calories consumed in low-fat consumers
Original publication
Orlistat mouth rinse: Using the tongue to deliver antiobesity medication in a double‐blind randomized crossover pilot trial. Diabetes Obes Metab. Published 3 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →